Article ID Journal Published Year Pages File Type
3977886 Brachytherapy 2012 11 Pages PDF
Abstract
HDR-ISBT may achieve good LC in gynecologic cancer unsuitable for ICB, especially in primary malignancies with a 2-year LC rate higher than 85%. Delivery of such high doses has potential advantages but may predispose to adverse effects, reversible in most cases.
Keywords
Related Topics
Health Sciences Medicine and Dentistry Oncology
Preview
Inverse-planned gynecologic high-dose-rate interstitial brachytherapy: Clinical outcomes and dose-volume histogram analysis
Authors
, , , , ,